Kazia Therapeutics Limited, a biotechnology company, develops anti-cancer drugs for patients suffering from glioblastoma, the most aggressive form of brain cancer. Through their innovative therapies, Kazia aims to improve patient outcomes and revolutionize the treatment landscape for this devastating disease.
